229 related articles for article (PubMed ID: 35384800)
21. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
[TBL] [Abstract][Full Text] [Related]
22. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
23. Immunosuppression in Liver Transplantation: State of the Art and Future Perspectives.
Nedredal GI; Picon RV; Chedid MF; Foss A
Curr Pharm Des; 2020; 26(28):3389-3401. PubMed ID: 32520679
[TBL] [Abstract][Full Text] [Related]
24. Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation.
Arora N; McKiernan PJ; Beath SV; deVille de Goyet J; Kelly DA
Pediatr Transplant; 2002 Jun; 6(3):214-8. PubMed ID: 12100505
[TBL] [Abstract][Full Text] [Related]
25. Calcineurin inhibitors in liver transplantation: to be or not to be.
Castroagudín JF; Molina E; Varo E
Transplant Proc; 2011; 43(6):2220-3. PubMed ID: 21839238
[TBL] [Abstract][Full Text] [Related]
26. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
27. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
[TBL] [Abstract][Full Text] [Related]
28. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
29. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
Pescovitz MD; Govani M
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S16-21. PubMed ID: 11583940
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study.
Hashim M; Alsebaey A; Ragab A; Soliman HE; Waked I
Ann Hepatol; 2020; 19(5):541-545. PubMed ID: 32768592
[TBL] [Abstract][Full Text] [Related]
31. Single-agent immunosuppression after liver transplantation: what is possible?
Raimondo ML; Burroughs AK
Drugs; 2002; 62(11):1587-97. PubMed ID: 12109922
[TBL] [Abstract][Full Text] [Related]
32. Management of long-term complications from immunosuppression.
Russo MW; Wheless W; Vrochides D
Liver Transpl; 2024 Jun; 30(6):647-658. PubMed ID: 38315054
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppression for older liver transplant recipients.
De Simone P; Battistella S; Lai Q; Ducci J; D'Arcangelo F; Marchetti P; Russo FP; Burra P
Transplant Rev (Orlando); 2024 Jan; 38(1):100817. PubMed ID: 38128152
[TBL] [Abstract][Full Text] [Related]
34. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
35. Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation.
Szumilas K; Wilk A; Wiśniewski P; Gimpel A; Dziedziejko V; Kipp M; Pawlik A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373448
[TBL] [Abstract][Full Text] [Related]
36. A Single-Center Experience of the Optimal Initial Immunosuppressive Strategy for Preventing Early Acute Cellular Rejection in Orthotopic Heart Transplantation Associated With Renal Dysfunction.
Mundisugih J; Fernando H; Bergin P; Hare J; Kaye D; Leet A; McGiffin D; Taylor AJ
Prog Transplant; 2019 Dec; 29(4):327-334. PubMed ID: 31476958
[TBL] [Abstract][Full Text] [Related]
37. Steroid or calcineurin inhibitor-sparing immunosuppressive protocols.
Grinyó JM; Cruzado JM
Contrib Nephrol; 2005; 146():30-42. PubMed ID: 15567918
[TBL] [Abstract][Full Text] [Related]
38. Calcineurin inhibitor-free protocols: risks and benefits.
Barbari AG; Stephan AG; Masri MA
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of de novo belatacept-based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization.
Petrossian G; Ortiz J; Ortiz AC; Koizumi N; Plews R
Nephrology (Carlton); 2022 Dec; 27(12):1006-1007. PubMed ID: 36251149
[No Abstract] [Full Text] [Related]
40. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
